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Obesity and type 2 diabetes mellitus (T2D) are two major public health problems that have motivated the scientific community to
investigate the high contribution of genetic factors to these disorders.The peroxisome proliferator activated by gamma 2 (PPAR𝛾2)
plays an important role in the lipid metabolism. Since PPAR𝛾2 is expressed mainly in adipose tissue, a moderate reduction of
its activity influences the sensitivity to insulin, diabetes, and other metabolic parameters. The present study aims to contribute
to the elucidation of the impact of the Pro12Ala polymorphism associated with T2D and obesity through a meta-analysis study
of the literature that included approximately 11500 individuals, from which 3870 were obese and 7625 were diabetic. Statistical
evidence supports protective effect in T2D of polymorphism Pro12Ala of PPAR𝛾2 (OR= 0.702 with 95% CI: 0.622; 0.791, 𝑃 <
0.01). Conversely the same polymorphism Pro12Ala of PPAR𝛾2 seems to favor obesity since 1.196 more chance than nonobese
was found (OR= 1.196 with 95% CI: 1.009; 1.417, 𝑃 < 0.004). Our results suggest that Pro12Ala polymorphism enhances both
adipogenic and antidiabetogenic physiological role of PPAR𝛾. Does Pro12Ala polymorphism represent an evolutionary step towards
the stabilization of the molecular function of PPAR𝛾 transcription factor signaling pathway?
1. Introduction
Peroxisome proliferator-activated receptors (PPARs) are
transcription factors from nuclear receptor’s protein fam-
ily that regulate target genes’ expression by connecting to
response elements of peroxisomes proliferators (PPERs) in
regulating sites of each gene. The signal transduction mech-
anism of these receptors involves retinol X receptor (RXR)
and PPARs form heterodimers that regulate the transcription
of several genes (Figure 1) [1–3].
Of all PPAR subtypes described, PPAR𝛼, PPAR𝛽, and
PPAR𝛾, the latter is the most studied [4]. The PPAR𝛾
gene, extended by a segment of over 150 kb, is localized in
chromosome 3, region 3p25, and is constituted by 3 isoforms:
PPAR𝛾1, PPAR𝛾2, and PPAR𝛾3, distinguished for generating
different promoters and alternative splicing [1, 5, 6].
PPAR𝛾2 is a transcriptional factor responsible for many
metabolic and cellular processes, such as cellular growth,
differentiation, and metabolism, in response to lipophilic
hormones, fatty acids, and its metabolites [1, 2]. It has high
affinity to fatty acids specific proliferators and is almost
exclusively expressed in the adipose tissue in humans, where
it modulates target genes expression involved in adipocytes
expression, insulin sensitivity, angiogenesis, and inflamma-
tory processes, among others (Figure 2) [1, 5–7].
To date, several PPAR𝛾2 polymorphisms have been
described and the Pro12Ala polymorphism has been associ-
atedwith variations of BMI and insulin sensitivity, depending
on the ethnicity, although the reasons for this heterogeneity
remain unclear [1, 7–9].
Given that PPAR𝛾2 is mainly expressed in adipose tissue
and taking in consideration the role of free fatty acids
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Figure 1: PPAR𝛾 transduction pathway. PPAR𝛾 has several extracellular and intracellular ligands that include dietary and bioactive lipids.
Given its antidiabetogenic role, some PPAR𝛾 ligands include antidiabetic drugs such as thiazolidinediones. PPAR𝛾 is also modulated by
several growth factor transduction pathways such as Jnk/Erk/MKP. It is also known that cyclin-dependent kinase 5 (Cdk5) bond to p25 (a
product of the cleavage of p35 in obesity environment) inhibits PPAR𝛾 pathway by its phosphorylation. As a transcriptional factor, PPAR𝛾
binds to RXR (retinol X receptor) in order to transcribe several genes related to adipocyte differentiation and lipid storage in adipose tissue
and increase insulin sensitivity in peripheral tissues by indirect increase of AMP kinase activity as well as several other antidiabetogenic
effects. Moreover, PPAR𝛾 blocks NF𝜅B signaling, thus reducing proinflammatory cytokines and inflammation.
(FFA) and adipokines in insulin regulation, the effect of the
Pro12Ala polymorphismmay be anticipated tomeasure these
factors alterations. Hence, individuals with the Ala12 allele
present have been described to have diminished lipoprotein
lipase activity [10], which can result in lipoproteins decrease
and, consequently, in plasmatic FA decrease, with harm to
insulin action in the skeletal muscle [11]. Accordingly, Ala12
allele carriers have been described to possess lower plasmatic
FA levels, higher blood flux in adipose tissue and skeletal
muscle, and higher insulin sensitivity [12]. Also, insulin
suppression resultant from the lipolysis process in adipose
tissue is increased in lean individuals as well in T2D patients
with the Ala12 allele [13, 14]. However, long term lipolysis
inhibition increases adiposity [13]. Still, these may not be
the real mechanism or the only mechanism subjacent to the
Pro12Ala polymorphism effect.
Obesity is classified as a multifactorial chronic disease
that consists in body fat accumulation in adipose tissue and
is globally recognized as an important public health issue,
affecting people of all ages and ethnicity that results in several
metabolic complications [15].
Diabetes mellitus is a metabolic disorder of multiple
etiologies, characterized by chronic hyperglycemia due to
deficient secretion or action of insulin and, like obesity, is
considered one of the main heath threats [16].
The present study pretends to contribute to the under-
standing of the role of the PPAR𝛾2 gene Pro12Ala poly-
morphism in two metabolic conditions, obesity and diabetes
mellitus 2 (T2D), through a systematic review and meta-
analysis.
2. Materials and Methods
We performed a systematic review and meta-analysis of
published works about the presence of particular PPAR𝛾
polymorphism such as Pro12Ala, as a risk factor for obesity
and for T2D, according to Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) guidelines.
2.1. Selection Criteria and Identification of Studies. The study
was conducted according to PRISMA directives. In order to
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Figure 2: Physiological andmetabolic roles of PPAR𝛾. In adipose tissue PPAR𝛾 is involved in lipid storage, which reduces circulating free fatty
acids (FFA). In adipose tissue PPAR𝛾 blocks the proinflammatory role of macrophages as well the secretion of resistin both by macrophages
and adipocytes which favors the uptake and metabolism of glucose in the liver, muscle, and other peripherals organs. Adipose tissue also
secretes adiponectin, which favors indirectly the activation of AMP kinase in the liver, heart, andmuscle. AMPK phosphorylates a number of
enzymes involved in fatty acid oxidation and glucose metabolism as well the synthesis and release of GLUT4. In the endothelial tissue, PPAR𝛾
favors the cholesterol efflux and at the same time, as consequence of the lowering of inflammatory signals, the recruitment of macrophages,
thus delaying the atherosclerosis. Overall, the outcome of downstream effectors results in the decrease of proinflammatory cytokines, free
fatty acids, and plasma glucose by increasing its uptake resulting in the increase of generalized insulin sensitivity and reduction of lipid
accumulation in the liver, cardiac and skeletal muscle, and arteries as well as the diminishing of chronic inflammation, prothrombotic state,
and atherosclerosis.
identify the studies, an electronic search, with no linguistic
restriction, was conducted, researching two databases, the
ScienceDirect and Medline (PubMed). The Boolean search
was conducted in both databases according to the following
keywords: (1) PPAR𝛾 [AND] Pro12Ala, (2) Pro12Ala [AND]
obesity, and (3) Pro12Ala [AND] diabetes mellitus 2.
Two investigators evaluated, independently, the titles and
abstracts of the papers identified as of potential relevance in
the inclusion criteria. Where a title or abstract could not be
included for certainty, a third corrector would help decide
whether to reject or not.
The papers that satisfied the initial inclusion criteria and
that were identified as of randomized or quasi-randomized
clinical trial conducted in human, and used the Pro12Ala
polymorphism as a comparison between control groups and
obese or diabetic groups, were then used for systematic
revision.
After the papers’ analysis, the data of interest was used
based on the place where the study was conducted, year of
publication, outcome, and number of individuals.
2.2. Statistics. The statistical analysis included false positives,
false negatives, true positives, and true negatives to establish
sensitivity and specificity and correlate both in a Roc curve,
𝑃 value, and odd ratios (OR), with and with a confidence
interval of 95%.
For the data analysis was used the program RevMan
version 5.1 and the SPSS Statistics version 17.0.
3. Results and Discussion
The research identified 11 studies, from which 6 were related
to the presence of Pro12Ala polymorphism in obesity and 8
to the presence of Pro12Ala polymorphism in T2D.
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Table 1: Included studies in the meta-analysis for obesity and respective genotype of the studied population.
Study Population Metabolicdisorder Participants
No. of cases
(O)
No. of control
(NO)
Genotype
Pro/Pro Pro/Ala Ala/Ala
O NO O NO O NO
Ghoussaini et al., 2005 [17] French Obesity(children) 591 396 195 304 156 84 39 8 0
Ghoussaini et al., 2005 [17] French Obesity(adults) 1713 1102 611 857 478 231 123 12 10
Gonza´lez Sa´nchez et al., 2002 [18] Spanish Obesity 459 145 314 119 264 25 50 1 3
Oh et al., 2000 [1] Korean Obesity 229 111 118 103 108 8 9 0 1
Ereqat et al., 2009 [19] Palestinian
Obesity
(T2D
individuals)
202 121 81 106 73 15 8 — —
Ben Ali et al., 2009 [20] Tunisian Obesity 675 387 288 348 271 39 17 — —
Summary 3869 2262 1607 1837 1350 402 246 21 14
Legend: T2D: type 2 diabetes mellitus; O: obese; NO: non-obese.
The studies related to obesity investigated a total of
3870 individuals, with 2260 being obese and 1610 nonobese
(Table 1).
The studies regarding the correlation between Pro12Ala
polymorphism and T2D investigated a total of 7625, with
4464 being diabetic and 3161 nondiabetic (Table 2).
The major characteristics of the investigated individuals
were similar in all included studies, as well as the methodol-
ogy.
The sensitivity analysis to evaluate population character-
istics was not possible due to the small number of included
studies.
Ali and collaborators studied the effect of Pro12Ala
polymorphism on obesity risk in a Tunisian population,
in 2009. They notice a significant difference between male
obese individuals and control and pointed out an association
between the polymorphism and obesity in nondiabetic male.
These individuals also displayed elevated BMI. However this
study did not proceed to body fat measurement or its distri-
bution in order to confirm the polymorphism contribution
in obesity. Still, it is supported the hypothesis that Pro12Ala
polymorphism is a relevant marker in nondiabetic Tunisian
man obesity, despite a noneffect on the individuals metabolic
characteristics [20].
Ereqat and collaborators studied obese Palestinian indi-
viduals with T2D. They notice the polymorphism was asso-
ciated with high plasmatic levels of total cholesterol, with
a tendency to increase LDL cholesterol levels. However,
there was no significant impact on BMI, triglycerides, or
arterial pressure. Hence, they concluded that the Ala12 allele
may influence cardiovascular risk, through effect on lipidic
metabolism, in obese Palestinian patients with T2D [19].
Ghoussaini and collaborators studied the French popula-
tion with T2D and obesity. Regarding obesity, they demon-
strated no association with Pro12Ala polymorphism, in chil-
dren or adults. Still they concluded that the polymorphism
confers a reduction in obesity risk [17].
Oh and collaborators conducted their study in the Korean
population. They found no significant association between
the Pro12Ala polymorphism and obesity, hypertension, or
dyslipidemia. However, despite the statistical nonsignifi-
cance, there is, according to the authors, the possibility of
PPAR𝛾2mutation having aminor effect on obesity, assuming
a significant effect if it occurs simultaneously with other
genes’ mutations or environmental factors [1].
Gonza´lez Sa´nchez and collaborators were the firsts to
conduct a population-based nationwide multicenter study in
Spain, suggesting that Pro12Ala polymorphism may promote
peripheral deposition of adipose tissue. The Ala12 allele
frequency was higher on obese male individuals than in lean
ones. Men carrying the Ala12 allele had a higher BMI than
noncarriers (38.9% versus 21.3%), despite possessing a lower
abdominal diameter [18].
Ghoussaini and collaborators studied the French popula-
tion with obesity and T2D, in 2005. Regarding the T2D study,
they affirmed that the polymorphism has a risk role, since a
significant association between the polymorphism and T2D
was found, with a 𝑃 value of 0.04 and OR = 1.37 (95% CI:
1.02; 1.85) [17].
Lindi and collaborators studied a diabetic Finnish pop-
ulation. They were the first to try an association between
Pro12Ala polymorphism and T2D incidence, in a high-risk
population with diminished glucose tolerance, in a longitu-
dinal study. No significant association of the Ala12 allele and
T2D incidence in the studied group [21] was found.
Chistiakov and collaborators analyzed Russian individ-
uals with T2D. Their results suggest that the polymorphism
reduces T2D risk, performing a protective role in this pathol-
ogy. In the studied population, the Pro12 allele contributes to
higher risk in developing T2D, according to OR = 1.69 (95%
CI: 1.02; 3.03) [22].
Oh and collaborators analyzed the association between
Pro12Ala polymorphism and T2D, in diabetic Koreans. They
compared individuals with normal and diminished glucose
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Table 2: Included studies in the meta-analysis for T2D and respective genotype of the studied population.
Study Population Metabolicdisorder Participants
No. of cases
(D)
No. of control
(ND)
Genotype
Pro/Pro Pro/Ala Ala/Ala
D ND D ND D ND
Ghoussaini et al., 2005 [17] French T2D + RIS 946 628 318 511 246 113 63 4 9
Lindi et al., 2002 [21] Finnish T2D 490 248 242 163 174 79 61 6 7
Chistiakov et al., 2010 [22] Russian T2D + RIS 1185 588 597 401 353 167 208 20 36
Oh et al., 2000 [1] Korean T2D 229 58 171 54 157 3 14 1 0
Bouassida et al., 2005 [23] Tunisian T2D 488 242 246 216 221 26 23 0 2
Malecki et al., 2003 [24] Polish T2D 644 366 278 256 202 99 66 11 10
Pinte´rova´ et al., 2004 [25] Czech T2D 230 133 97 99 61 31 30 3 6
Mori et al., 2001 [26] Japanese T2D 3413 2201 1212 2097 1114 103 96 1 2
Summary 7625 4464 3161 3797 2528 621 561 46 72
Legend: T2D: type 2 diabetes mellitus; D: diabetic; ND: non-diabetic; RIS: reduced insulin sensitivity.
Table 3: Sensitivity and specificity for Pro12Ala polymorphism and obesity.
Study TP FP FN TN Sensitivity Specificity
Ben Ali et al., 2009 [20] 39 17 348 271 0.10 [0.07, 0.14] 0.94 [0.91, 0.97]
Ereqat et al., 2009 [19] 15 8 106 73 0.12 [0.07, 0.20] 0.90 [0.81, 0.96]
Ghoussaini et al., 2005 [17] 243 133 857 478 0.22 [0.20, 0.25] 0.78 [0.75, 0.81]
Ghoussaini et al., 2005 [17] 92 39 304 156 0.23 [0.19, 0.28] 0.80 [0.74, 0.85]
Oh et al., 2000 [1] 8 10 103 108 0.07 [0.03, 0.14] 0.92 [0.85, 0.96]
Gonza´lez Sa´nchez et al., 2002 [18] 26 53 314 156 0.08 [0.05, 0.11] 0.75 [0.68, 0.80]
tolerance and with diabetes. No significant differences were
found among Ala12 allele frequency in the study groups,
concluding an inexistent significant association between
Pro12Ala polymorphism and T2D. However, despite these
results, they affirm that there is the possibility of an effect,
at minor scale, of the polymorphism on the pathology, when
associated with other mutations on other genes, as well with
environmental factors [1].
Bouassida and collaborators studied the association of
Pro12Ala polymorphism and Tunisian T2D carriers. They
concluded that there was no significant differences between
diabetic and control groups and that, therefore, the polymor-
phism does not display a role in the pathology [23].
Malecki and collaborators studied the Pro12Ala poly-
morphism with T2D incidence in a polish population. They
compared the polymorphism incidence in a diabetic and a
nondiabetic (control) group and notice that the Pro12 and
Ala12 alleles’ frequency were similar (83.5% and 16.5% versus
84.5% and 15.5%, resp., 𝑃 = 0.607), as well as the genotypic
distribution.They could not conclude that the polymorphism
confers higher risk to T2D susceptibility, as in numerous
European studies in Caucasians [24].
Pinte´rova´ and collaborators, in 2004, wanted to under-
stand the association between the Pro12Ala polymorphism
and T2D. In order to do so, they studied the Czech popula-
tion, comparing a study group of 133 diabetic individuals to
a nondiabetic control group of 97 individuals. In the study
group, 3 individuals (2.26%) were identified as homozygotes
for the Ala/Ala genotype, 99 individuals (74.44%) were
identified as homozygotes for the Pro/Pro genotype, and
31 individuals (23.31%) were identified as heterozygotic. In
the control group, 6 individuals (6.19%) were identified
as homozygotes for the Ala/Ala genotype, 61 individuals
(62.89%) were identified as homozygotes for the Pro/Pro
genotype, and 30 individuals (30.93%) were identified as
heterozygotic. The allelic frequency for the Ala allele was
lower in the diabetic group (13.91% versus 21.43% for control
group, 𝑃 = 0.022).There was no difference (𝑃 = 0.05) among
phenotypic characteristics (BMI, gender) in the studied
group regarding genotype Pro12Ala. Therefore this study
supports the hypothesis that the polymorphism plays an
important role in T2D for the Czech population. The results
showed that the allelic frequency of for Ala12 is higher in
control group than in study group.Overall the polymorphism
is associated with reduced risk of T2D, assuming a protective
role in the pathology [25].
Mori and collaborators analyzed the polymorphism and
T2D in a Japanese population. They included in their study
2201 individuals with T2D (study group) and 1212 individuals
without the pathology (control group). The allelic frequency
of Ala12 was higher in in control group (4.13% versus 2.39%
for the study group).They concluded that the polymorphism
is associated with reduced risk of T2D development, acting
out protectively factor in the pathology [26].
3.1. Meta-Analysis Results. The combination of the studies
that analyzed the presence of Pro12Ala polymorphism in
obesity is showed on Table 3.
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Table 4: Sensitivity and specificity for Pro12Ala polymorphism and T2D.
Study TP FP FN TN Sensitivity Specificity
Bouassida et al., 2005 [23] 26 25 216 221 0.11 [0.07, 0.15] 0.90 [0.85, 0.93]
Chistiakov et al., 2010 [22] 187 244 401 353 0.32 [0.28, 0.36] 0.59 [0.55, 0.63]
Ghoussaini et al., 2005 [17] 117 68 511 246 0.19 [0.16, 0.22] 0.78 [0.73, 0.83]
Lindi et al., 2002 [21] 85 68 163 174 0.34 [0.28, 0.41] 0.72 [0.66, 0.77]
Malecki et al., 2003 [24] 110 76 256 202 0.30 [0.25, 0.35] 0.73 [0.67, 0.78]
Mori et al., 2001 [26] 104 98 2097 1114 0.05 [0.04, 0.06] 0.92 [0.90, 0.93]
Oh et al., 2000 [1] 4 14 54 157 0.07 [0.02, 0.17] 0.92 [0.87, 0.95]
Pinte´rova´ et al., 2004 [25] 34 36 99 61 0.26 [0.18, 0.34] 0.63 [0.52, 0.72]
Regarding the presence of Pro12Ala polymorphism in
T2D, the combination of all included studies is presented in
Table 4.
Eleven studies that investigated the Pro12Ala polymor-
phism were included in the present meta-analysis. From
these, 6 studies investigated the hypothetical association
of the polymorphism and obesity and 8 investigated the
hypothetical association of the polymorphism, Tables 1 and 2.
The data was then aggregated according to presence/absence
of the polymorphism and presence/absence of the pathol-
ogy. Individuals with the genotype Pro/Pro did not possess
the polymorphism and individuals with genotype Pro/Ala
(heterozygotes) and genotypeAla/Ala (homozygotes) possess
the polymorphism. This way, it was possible to assort all
individuals in TN, FN, TP, and FP and, with these data, obtain
the sensitivity and specificity graphics (Tables 3 and 4). The
analysis of these tables allowed concluding that the studies
are not sensitive but very specific.
In Table 3, Ghoussaini and collaborators’ study [17] con-
ducted in obese children represented themost sensitive study,
with a value of 0.23 (95% CI: 0.19; 0.28). On the other
hand, Oh and collaborators [1] had the least sensitive study,
with 0.07 (95% CI: 0.03; 0.14). The study with the highest
average specificity belongs to Ben Ali and collaborators [20],
conducted in 2009, with a specificity value of 0.94 (95% CI:
0.91; 0.97) and the one with the lowest average specificity was
conducted by Gonza´lez Sa´nchez and collaborators, 0.75 (95%
CI: 0.68; 0.80).
In Table 4, Lindi and collaborators’ study [21] represented
the most sensitive study, with a value of 0.34 (95% CI:
0.28; 0.41). On the opposite side, Mori and collaborators
[26] had the least sensitive study, with 0.05 (95% CI: 0.04;
0.06). The latter also had the study with the highest average
specificity, with 0.92 (95%CI: 0.90; 0.93) and the one with the
lowest average specificity was conducted by Chistiakov and
collaborators [22], 0.59 (95% CI: 0.55; 0.63).
The results from these tables allowed constructing the
respective ROC curve (not shown) and we conclude that
the Pro12Ala polymorphism is not a good test (regarding
sensitivity and specificity) to predict the presence of obesity,
since the test line is very close to the random line. The
same conclusion can be taken from the analysis of the
Pro12Ala polymorphism which is not a good test to predict
the presence of T2D.
Table 5: Pro12Ala polymorphism and obesity.
Obesity Total 𝑃 value
Obese Non-obese
Polymorphism Pro12Ala
Present 423 260 683
𝑃 < 0.004Non-present 1837 1350 3187
Total 2260 1610 3870
Table 6: Pro12Ala polymorphism and T2D.
T2D Total P value
Diabetic Non-diabetic
Polymorphism Pro12Ala
Present 667 633 1300
𝑃 < 0.01Non-present 3797 2528 6325
Total 4464 3161 7625
Table 7: Estimated risk of the Pro12Ala polymorphism with obesity.
Value 95% CI
Low High
OR for polymorphism Pro12Ala (0/1) 1.196 1.009 1.417
OR for variable non-obese = 0 1.113 1.003 1.235
OR for variable obese = 1 0.931 0.871 0.994
Number of valid cases 3870
Table 8: Estimated risk of the Pro12Ala polymorphism with T2D.
Value 95% CI
Low High
OR for polymorphism Pro12Ala (0/1) 0.702 0.622 0.791
OR for variable non-diabetic = 0 0.940 0.920 0.961
OR for variable diabetic = 1 1.340 1.214 1.479
Number of valid cases 7625
We also proceed to the determination of the odds ratio
(OR) and 𝑃 values, by the Chi-squared test. Tables 5 and 6
show the𝑃 value for obesity and T2D, respectively, and Tables
7 and 8 show the risk estimative (OR) for the variables used
in this meta-analysis, with a 95% CI, for obesity and T2D,
respectively.
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Regarding the association between the polymorphism
and obesity, obese individuals possess a 1.196 more chance
of carrying the polymorphism than non-obese (OR = 1.196
with 95% CI: 1.009; 1.417. 𝑃 < 0.004).
Concerning the association between the polymorphism
and T2D, diabetic individuals possess a 0.702 less chance of
carrying the polymorphism than nondiabetic (OR = 0.702
with 95% CI: 0.622; 0.791. 𝑃 < 0.001).
Therefore, the Pro12Ala polymorphism from gene
PPAR𝛾2 acts out as a risk factor in obesity (𝑃 < 0.05 and
OR = 1.196 with CI values that never include 1) and as a
protective factor for T2D (𝑃 < 0.05 and OR = 0.702 with
CI values that never include 1), by the evident statistical
significance.
4. Conclusions
Comparing results obtained from thismeta-analysis and each
of the included studies, we can verify some differences.There
are studies that conclude that Pro12Ala polymorphism is a
risk factor in obesity or T2D, while others conclude the
opposite for both pathologies. There are also studies that
do not have statistically significant data to support either
conclusion.
Ben Ali et al. [20], Ghoussaini et al. [17], Oh et al. [1],
and respective collaborators could not associate, from their
studies, the polymorphism presence in obesity. Meanwhile
Gonza´lez Sa´nchez and collaborators [18] associated the poly-
morphism with higher risk of obesity. Ereqat and collabora-
tors [19] associated the polymorphism to lipidic metabolism
in obese Palestinian individuals with T2D, concluding that
the Ala allele presence may influence cardiovascular risk.
Results regarding the role of the polymorphism in T2D,
Boussida et al. [23], Lindi et al. [21], Malecki et al. [24], Oh
et al. [1], and their respective collaborators, could not obtain
significative results and, consequently, could not associate
the polymorphism to the T2D presence. Chistiakov et al.
[22], Mori et al. [26], Pinte´rova´ et al. [25], and collaborators
had agreeing results with the ones obtained in this meta-
analysis, pointing out the polymorphism’s protective effect in
T2D. Contrariwise Ghoussaini et al. [17] and collaborators
sustained that the polymorphism plays a risk factor in the
pathology.
Association studies clearly show this gene’s regulation in
adipose tissue is a complex process. Several studies suggest
that genetics or the environment (such as diet) participates
in the formation of association patterns of Pro12Ala poly-
morphism with body mass in different human populations.
Numerous studies have also clearly showed the hetero-
geneous effects of Pro12Ala polymorphism in decreased
risk of T2D several populations. Considering that the two
pathologies are multifactorial it is difficult to clarify the
real contribution that the polymorphism makes in these
metabolic disorders.
The present study includes approximately 11500 individ-
uals, from which 3870 are obese and 7625 are diabetic. From
our results we concluded that the Pro12Ala polymorphism
from PPAR𝛾2 gene has a protective role in T2D but is
a risk factor for obesity accordingly with what we should
expected substitute to for about to the physiological role of
PPAR𝛾 itself. It seems that the Pro12Ala polymorphism may
be a transitory state towards the structural and functional
stabilization of the gene role in human kind, resembling a
genetic drift at the molecular level.
Therefore, this study supports the need of investment for
further research, mainly by population genetics, in order to
fully understand the role of this polymorphism in the PPAR𝛾
cascades.
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